Evoke Pharma Inc
EVOK11.000USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
18.95MMarket Cap
LossP/E TTM
More Details of Evoke Pharma Inc Company
Evoke Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal disorders and diseases. It develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. It has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.
Evoke Pharma Inc Info
Ticker SymbolEVOK
Company nameEvoke Pharma Inc
IPO dateSep 25, 2013
CEOD'Onofrio (Matthew J)
Number of employees3
Security typeOrdinary Share
Fiscal year-endSep 25
Address420 Stevens Avenue
CitySOLANA BEACH
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92075
Phone18583451494
Websitehttps://evokepharma.com/
Ticker SymbolEVOK
IPO dateSep 25, 2013
CEOD'Onofrio (Matthew J)
Company Executives of Evoke Pharma Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Matthew J. (Matt) D'Onofrio
Mr. Matthew J. (Matt) D'Onofrio
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
9.82K
+15.50%
Mr. Cam L. Garner
Mr. Cam L. Garner
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
2.33K
-0.04%
Dr. Malcolm R. Hill, Pharm.D.
Dr. Malcolm R. Hill, Pharm.D.
Independent Director
Independent Director
133.00
-0.75%
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
Independent Director
Independent Director
27.00
-3.57%
Mr. Greg Pyszcymuka
Mr. Greg Pyszcymuka
Independent Director
Independent Director
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--
Dr. Marilyn R. Carlson, M.D.
Dr. Marilyn R. Carlson, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Benjamin C. (Ben) Smeal
Mr. Benjamin C. (Ben) Smeal
Independent Director
Independent Director
--
--
Mr. Daniel Kontoh-Boateng
Mr. Daniel Kontoh-Boateng
Investor Contact
Investor Contact
--
--
Ms. Vickie W. Reed
Ms. Vickie W. Reed
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Matthew J. (Matt) D'Onofrio
Mr. Matthew J. (Matt) D'Onofrio
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
9.82K
+15.50%
Mr. Cam L. Garner
Mr. Cam L. Garner
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
2.33K
-0.04%
Dr. Malcolm R. Hill, Pharm.D.
Dr. Malcolm R. Hill, Pharm.D.
Independent Director
Independent Director
133.00
-0.75%
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
Independent Director
Independent Director
27.00
-3.57%
Mr. Greg Pyszcymuka
Mr. Greg Pyszcymuka
Independent Director
Independent Director
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2024Q1
FY2023
FY2022
FY2021
FY2020
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
3.75M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: 21 hours ago
Updated: 21 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Klein (Roger M.)
9.46%
Bleichroeder LP
8.50%
National Wealth Management Group, LLC
4.65%
DRW Securities, LLC
1.38%
The Vanguard Group, Inc.
1.09%
Other
74.92%
Shareholders
Shareholders
Proportion
Klein (Roger M.)
9.46%
Bleichroeder LP
8.50%
National Wealth Management Group, LLC
4.65%
DRW Securities, LLC
1.38%
The Vanguard Group, Inc.
1.09%
Other
74.92%
Shareholder Types
Shareholders
Proportion
Investment Advisor
15.82%
Individual Investor
10.62%
Hedge Fund
9.21%
Investment Advisor/Hedge Fund
0.45%
Research Firm
0.02%
Other
63.88%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
25
502.38K
22.98%
--
2025Q3
26
502.38K
25.40%
+260.79K
2025Q2
25
242.44K
26.58%
-10.18K
2025Q1
28
252.99K
24.26%
-109.24K
2024Q4
30
218.46K
24.86%
-81.81K
2024Q3
31
208.32K
29.69%
-54.34K
2024Q2
31
262.66K
432.25%
-959.00
2024Q1
39
263.62K
30.12%
+47.85K
2023Q4
36
5.70K
3.76%
+99.00
2023Q3
40
5.65K
7.83%
+642.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bleichroeder LP
68.75K
4.41%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
1.71K
0.11%
--
--
Aug 31, 2025
D'Onofrio (Matthew J)
9.82K
0.63%
+1.32K
+15.50%
Mar 24, 2025
Geode Capital Management, L.L.C.
7.86K
0.5%
-19.00
-0.24%
Aug 31, 2025
Kowieski (Mark A.)
4.92K
0.32%
+4.92K
--
Mar 24, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
Date
Type
Ratio
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
FAQs
Who are the top five shareholders of Evoke Pharma Inc?
The top five shareholders of Evoke Pharma Inc are:
Bleichroeder LP holds 68.75K shares, accounting for 4.41% of the total shares.
The Vanguard Group, Inc. holds 1.71K shares, accounting for 0.11% of the total shares.
D'Onofrio (Matthew J) holds 9.82K shares, accounting for 0.63% of the total shares.
Geode Capital Management, L.L.C. holds 7.86K shares, accounting for 0.50% of the total shares.
Kowieski (Mark A.) holds 4.92K shares, accounting for 0.32% of the total shares.
Bleichroeder LP holds 68.75K shares, accounting for 4.41% of the total shares.
The Vanguard Group, Inc. holds 1.71K shares, accounting for 0.11% of the total shares.
D'Onofrio (Matthew J) holds 9.82K shares, accounting for 0.63% of the total shares.
Geode Capital Management, L.L.C. holds 7.86K shares, accounting for 0.50% of the total shares.
Kowieski (Mark A.) holds 4.92K shares, accounting for 0.32% of the total shares.
What are the top three shareholder types of Evoke Pharma Inc?
The top three shareholder types of Evoke Pharma Inc are:
Klein (Roger M.)
Bleichroeder LP
National Wealth Management Group, LLC
Klein (Roger M.)
Bleichroeder LP
National Wealth Management Group, LLC
How many institutions hold shares of Evoke Pharma Inc (EVOK)?
As of 2025Q4, 25 institutions hold shares of Evoke Pharma Inc, with a combined market value of approximately 502.38K, accounting for 22.98% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -2.42%.
What is the biggest source of revenue for Evoke Pharma Inc?
In FY2025Q2, the -- business generated the highest revenue for Evoke Pharma Inc, amounting to -- and accounting for --% of total revenue.
